The global HER2 Positive Gastric Cancer Market is worth US$ 1.26 Billion as of now and expected to reach US$ 1.78 Billion by the year 2033 at a CAGR of 3.5% between 2023 and 2033.
Stomach cancer cells have an excessive quantity of growth-promoting protein termed as ‘HER2’ on their surface. Cancers having an increased level of HERS are termed as ‘HER2-positive’. The drugs targeting HER2 protein could be of great help in the treatment of these cancers.
He regulatory authorities are also approving GER2-positive gastric cancer drugs. On these grounds, Enhertu was approved by the US FDA in January 2021. It is an antibody-drug conjugate product meant to treat HER2-positive metastatic gastric cancers.
Stay Informed: Discover the Potential of the HER2 Positive Gastric Cancer Market with Our Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16232
The geriatric population is also contributing toward growth of HER2 positive gastric cancer market. There are vices like smoking and alcoholism to add (for all the age groups above teenage).
At the same time, the fact that there is still a lack of understanding regarding intratumoral heterogeneity and non-uniformity of regulations worldwide can’t be ignored. This factor may restrain the HER2 positive gastric cancer market going forward.
Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘HER2 Positive Gastric Cancer Market’. It has its line of expertise in the form of analyst and consultants to look through the bottom-up approach in its primary, secondary, and tertiary modes of research.
“With a deeper focus on developing all the more effective treatment procedures along with advanced drugs, the global HER2 Positive Gastric Cancer Market is bound to grow on an irrevocable note in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from HER2 Positive Gastric Cancer Market
- North America holds the largest market share with the US housing a plethora of cancer-afflicted patients.
- Europe and the Asia-Pacific stand second and third respectively on the similar grounds and the status quo is expected to remain unchanged even in the forecast period.
Our analyst is available to help you with any inquiries you may have @ https://www.futuremarketinsights.com/ask-question/rep-gb-16232
Competitive Analysis
- The US FDA, in May 2021, did access accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in conjunction with fluoropyrimidine, trastuzumab, and platinum-containing chemotherapy for the very first line treatment of the patients with locally advanced metastatic or unresectable HER2 positive gastric/gastroesophageal junction (GEJ) adenocarcinoma.
- CytoReason, in September 2022, did announce extending its multi-year partnership with Pfizer for using its AI technology for the latter’s drug development programs.
- Shanghai Henlius Biotech, Inc., in December 2022, did announce about the first patient being dosed in phase 1 clinical trial (NCT053941168) of HLX53 (an anti-TIGIT Fc fusion protein) to treat metastatic solid tumors/lymphomas in China.
- Novocodex Biopharmaceuticals is known for developing antibodies to treat cancer. The company is into designing biopharmaceutical anti-HER2 – a monoclonal antibody-conjugated drug via non-natural amino acid insertion technology to couple toxins on mAb. It could be used to treat HER2, gastric cancer, and positive recurrent breast cancer.
- VCell makes provisions for biosimilar products to cure autoimmune diseases. Remsima is basically used for treating autoimmune diseases like ankylosing spondylitis and rheumatoid arthritis. Truxima anti-tumor biosimilar product is used for treating non-Hodgkin’s lymphoma and various other hematological tumors apart from rheumatoid arthritis. HER2 positive breast and gastric cancer could be treated through Herzuma.
- Abscint does offer ABSCINT-HER2 to detect HER2 positive cells in brains. ABSCINT-206 is used to detect immune cells in granuloma CD-206 positive macrophages in heart.
- ASLAN Pharmaceuticals is known for providing drugs to treat breast, bile duct, and gastric cancers. The most advanced compound is ASLAN001 that is pan-HER inhibitor with phase 2 data in gastric cancer. ASLAN002 does target RON (an immune checkpoint inhibitor) with cMET tyrosine kinases pertaining to breast and gastric cancer.
Your Market, Your Insights: Request Customizations to Optimize Your HER2 Positive Gastric Cancer Market Approach @ https://www.futuremarketinsights.com/customization-available/rep-gb-16232
What does the Report Cover?
- The research study is based on therapy (chemotherapy, immunotherapy, radiation therapy, and targeted therapy), stage (Stage I, Stage II, Stage III, and Stage IV), and end-user (ambulatory surgery centers, hospitals and specialty clinics, and likewise).
- With increasing approval of the pipeline candidates, the global HER2 positive gastric cancer market is expected to grow inadvertently in the forecast period.
Key Companies Profiled:
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
- Hutchison Medipharma
- LintonPharm
- Shanghai Henlius Biotech
- Sanofi
- Pfizer
- Novartis AG
Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey
HER2 Positive Gastric Cancer Market by Therapy:
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
Get Ahead with Detailed Market Intelligence: Purchase Now to Access @ https://www.futuremarketinsights.com/checkout/16232
HER2 Positive Gastric Cancer Market by Stage:
- Stage I
- Stage II
- Stage III
- Stage IV
HER2 Positive Gastric Cancer Market by End-User:
- Ambulatory surgery centers,
- Hospitals and Specialty clinics
- Others
HER2 Positive Gastric Cancer Market by Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia-Pacific
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
